| Form | Liquid |
|---|
| Host Species | Humanized |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-kappa |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | Q9NR61 & P15692 |
|---|
| Background | Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.
|
|---|
| Alternative Names | Bispecific, ABT-165, PR-1283233, 1791420-09-1 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|